Tech Startups Apply for Fall RAMP Cohort

RAMP is accepting applications are for their fall cohort to begin in September 2021.

RAMP is looking for technology startups with scalability, and coachable entrepreneurs who have a desire to do the work.

RAMP will select up to five companies for the 12-week cohort that provides:

• Expert 1:1 mentoring with the region’s top entrepreneurs and executives
• Free office space with high-speed internet in downtown Roanoke in Virginia’s Blue Ridge
• Access to venture capital
• $20,000 in equity-free funding

Application Close Date: August 15 Cohort

Start Date: September 13

DEMO DAY (tentative): December 9

Visit here to apply.

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing …

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to …

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like …

News